...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of immunogenetics >Human leukocyte antigen‐G in gynaecological tumours
【24h】

Human leukocyte antigen‐G in gynaecological tumours

机译：Human leukocyte antigen‐G in gynaecological tumours

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

Abstract Gynaecological tumours that threaten the health of women, especially when advanced and recurrent, have remained mostly intractable to existing treatments. Therefore, new therapeutic targets are urgently needed. Human leukocyte antigen‐G (HLA‐G) is a nonclassical major histocompatibility complex class I molecule typically expressed in foetuses for protection against destruction by the maternal immune system. HLA‐G is also expressed under pathological conditions, such as in solid tumours, and may participate in tumour development and serve as a novel immune checkpoint in cancer. Furthermore, it is expressed in most gynaecological tumours. Therefore, inhibiting HLA‐G and its receptors to block the immune escape pathway could represent a new strategy in cancer immunotherapy. To the best of our knowledge, this review is the first to summarize recent research findings on HLA‐G in gynaecological oncology. We highlight the fact that HLA‐G is expressed in gynaecological tumour tissues, wherein it inactivates immune effectors involved in tumour progression. Further studies on HLA‐G in gynaecological oncology are needed to incorporate HLA‐G into the design and evaluation of immunotherapy for malignant gynaecological diseases.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号